Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Stealth BioTherapeutics Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 5 examiners and 4 art units, indicating both examiner diversity and some concentration within technical groups.
SHTERENGARTS, SAMANTHA L is the busiest examiner, with 2 pending matters. That assignment is the clearest examiner concentration in the portfolio, but other matters require coordination across additional examiner relationships.
The 4 art units support technical grouping for internal review. Counsel can compare recurring claim and prior-art issues within those groups while preserving responses that address each examiner’s record.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| TIEN, LUCY MINYU | 1 | 59.1% | +36.8% |
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18135314 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | FISCHER, JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285570 | SILICA-BASED FORMULATIONS OF THERAPEUTIC OLIOGPEPTIDES AND PEPTIDOMIMETICS | TIEN, LUCY MINYU | 7d |
| 18672743 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY | GEMBEH, SHIRLEY V | 20d |
| 18011354 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | KATAKAM, SUDHAKAR | 26d |
| 18135314 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | FISCHER, JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1615 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18672743 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY | GEMBEH, SHIRLEY V | 1615 | Other | Final Rejection | 20d | Pending | May 23, 2024 |
| 18285570 | SILICA-BASED FORMULATIONS OF THERAPEUTIC OLIOGPEPTIDES AND PEPTIDOMIMETICS | TIEN, LUCY MINYU | 1612 | §103DP | Final Rejection | 7d | Pending | Oct 04, 2023 |
| 18135314 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | FISCHER, JOSEPH | 1658 | §102§103§112 | Non-Final OA | — | Pending | Apr 17, 2023 |
| 18011354 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | 26d | Pending | Dec 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStealth BioTherapeutics Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Shirley V Gembeh has the most, with 1 of Stealth BioTherapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
